Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | CDA | P32320 | 1/20 | 0.34 |
| ▸ | PYGM | P11217 | 1/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631485 | 0.89 | KDM4E (0.40) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631446 | 0.88 | CDK1 (0.42) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631542 | 0.83 | MAPT (0.36) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631699 | 0.82 | MAPT (0.35) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631604 | 0.82 | MAPT (0.35) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL18080251 | 0.81 | P2RY2 (0.51) | P2RY2 | |
| SCHEMBL16631657 | 0.79 | PYGM (0.36) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631328 | 0.79 | SLC28A1 (0.45) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631645 | 0.78 | LMNA (0.39) | MAPTKDM4EGMNNLMNABLM | |
| SCHEMBL16631484 | 0.77 | PNP (0.39) | MAPTKDM4EGMNNLMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | MAPT 3290/4885KDM4E 4689/4885GMNN 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.